Trial Profile
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Trabectedin (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- Acronyms TOMAS
- 18 Oct 2023 According to PharmaMar media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) congress
- 13 Apr 2021 Status changed from recruiting to completed.
- 05 Aug 2019 Planned number of patients changed from 40 to 50.